Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation.

Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE.

Trends Pharmacol Sci. 2007 Jul;28(7):316-25. Epub 2007 Jun 18. Review.

PMID:
17573127
2.

Efficacy and safety of varenicline for smoking cessation.

Hays JT, Ebbert JO, Sood A.

Am J Med. 2008 Apr;121(4 Suppl 1):S32-42. doi: 10.1016/j.amjmed.2008.01.017. Review.

PMID:
18342165
3.

Varenicline: for smoking cessation.

Rao J, Shankar PK.

Kathmandu Univ Med J (KUMJ). 2009 Apr-Jun;7(26):162-4. Review.

PMID:
20071853
4.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
5.

The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.

Foulds J.

Int J Clin Pract. 2006 May;60(5):571-6. Review.

PMID:
16700857
6.

[New drugs; varenicline].

van Bronswijk H, Dubois EA, Zitman FG, Cohen AF.

Ned Tijdschr Geneeskd. 2007 Nov 10;151(45):2503-4. Dutch.

PMID:
18062594
7.

Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, Sands SB, Schaeffer E, Schulz DW, Tingley FD 3rd, Williams KE.

Neuropharmacology. 2007 Mar;52(3):985-94. Epub 2006 Dec 8.

PMID:
17157884
8.

The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review.

Crunelle CL, Miller ML, Booij J, van den Brink W.

Eur Neuropsychopharmacol. 2010 Feb;20(2):69-79. doi: 10.1016/j.euroneuro.2009.11.001. Epub 2009 Dec 3. Review.

PMID:
19959340
9.
10.
11.

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O'Neill BT.

J Med Chem. 2005 May 19;48(10):3474-7.

PMID:
15887955
12.
13.
15.
16.

Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation.

Tutka P.

Expert Opin Investig Drugs. 2008 Oct;17(10):1473-85. doi: 10.1517/13543784.17.10.1473 . Review.

PMID:
18808308
17.

Varenicline: progress in smoking cessation treatment.

Glover ED, Rath JM.

Expert Opin Pharmacother. 2007 Aug;8(11):1757-67. Review.

PMID:
17685891
18.

Varenicline for smoking cessation.

Tonstad S.

Expert Rev Neurother. 2007 Feb;7(2):121-7. Review.

PMID:
17286546
19.

[Pharmacological profile and clinical findings on varenicline tartrate (Champix tablets)].

Hizue M, Ishibashi T, Nomura S.

Nihon Yakurigaku Zasshi. 2010 May;135(5):194-203. Review. Japanese. No abstract available.

PMID:
20467169
20.

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.

Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K.

Arch Intern Med. 2006 Aug 14-28;166(15):1571-7.

PMID:
16908789

Supplemental Content

Support Center